Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

2

About Jing Li

Jing Li is the co-founder of Dianping.

Jing Li Headquarter Location

Beijing,

China

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Jing Li News

High Expression of miR-196b Predicts Poor Prognosis in Patients with Ovarian Cancer

Oct 1, 2020

Yang Li,1 Jing Li,2 Zirong Liu,1 Yamin Zhang1 1Department of Hepatobiliary Surgery, Tianjin First Central Hospital, Tianjin 300192, People’s Republic of China; 2Department of Gynaecology, Tianjin First Central Hospital, Tianjin 300192, People’s Republic of China Correspondence: Yamin Zhang Department of Hepatobiliary Surgery Tianjin First Central Hospital, Tianjin 300192, People’s Republic of China Email gandanliyang@163.com Background/Aims: To analyze the clinical significance of miR-196b expression in ovarian cancer and predict the function and possible mechanism of miR-196b. Methods: Both Kaplan–Meier (K-M) and Cox proportional hazards regression model were used to analyze the prognostic factors of patients with ovarian cancer. MiR196-b was modulated in ovarian cancer cells, and the cell viability, cell cycle, and cell cycle-related gene expression were analyzed. The target genes of miR-196b were then predicted and checked the relationship between the target genes. Results: MiR-196b was an independent risk factor, while high expression of miR-196b was associated with poor prognosis of ovarian cancer. MiR-196b overexpression increased cancer cell proliferation. Cdkn1b, as one of the targets of miR-196b, was related to cell viability and mitosis. Conclusion: High expression of miR-196b was significantly associated with poor prognosis of the patients with ovarian cancer. MiR-196b could increase the cell proliferation of ovarian cancer by modulating Cdkn1b expression. Keywords: microRNAs, MiR-196b, ovarian cancer, Cdkn1b, proliferation This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License . By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms .

Jing Li Investments

2 Investments

Jing Li has made 2 investments. Their latest investment was in Fantuan Delivery as part of their Series B on January 1, 2021.

CBI Logo

Jing Li Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/12/2021

Series B

Fantuan Delivery

$35M

No

7

3/19/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/12/2021

3/19/2020

Round

Series B

Series A

Company

Fantuan Delivery

Subscribe to see more

Amount

$35M

$99M

New?

No

Subscribe to see more

Co-Investors

Sources

7

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.